SL Science Presents New Data on γδ T Cells for Glioblastoma Treatment

TAIPEI, Taiwan, Sept. 24, 2026 /CourierPR/ -- SL Science Holding Limited, a Taiwan-headquartered biomedical company, has announced new preclinical data at the 85th Annual Meeting of the Japanese Cancer Association, held from September 24-26, 2026. The findings, presented as poster P-2017, highlight the potential of unmodified human γδ T cells in targeting chemotherapy-resistant glioblastoma (GBM).

The research, conducted in collaboration with investigators from Taipei Medical University (TMU), JY BioMed, and HeXun Biosciences, demonstrates the GDT cell platform's ability to preferentially destroy MGMT-positive tumor cells. These cells are typically resistant to standard chemotherapy and drive disease recurrence. The poster presentation includes several key data points that support the efficacy of the γδ T cells.

In advanced laboratory models, γδ T cells showed a higher cytotoxicity toward MGMT-positive GBM cells, which are often left unharmed by conventional treatments. Real-time analysis across three distinct GBM cell lines (U87MG, T98G, and LN229) revealed a dose-dependent reduction in tumor cells upon the addition of γδ T cells. The γδ T cells exhibited superior cancer-killing activity compared to conventional αβ T cells in direct in vitro comparisons.

In vivo studies confirmed the therapy's potential, as contextual data showed a reduction in tumor size and prolonged survival in an intracranial GBM model. The therapy was well-tolerated, with no obvious adverse findings. These results suggest that γδ T cells can effectively target the specific fraction of the tumor that standard chemotherapy struggles to eliminate.

Glioblastoma is traditionally treated with surgery, radiotherapy, and the chemotherapy drug temozolomide. However, tumors often recur due to the MGMT repair enzyme, which allows cancer cells to survive treatment. The new data show that SL Science's γδ T cells directly address this chemo-resistant population. Because γδ T cells recognize general stress signals on cancer cells rather than relying on a single antigen, their cancer-killing ability is not hindered by the tumor's DNA-repair mechanisms.

This presentation marks the third recent milestone in a defined development sequence for the Company. It follows a July presentation in Melbourne demonstrating the therapy's ability to control tumor growth in vivo and an August peer-reviewed publication outlining the clinical development requirements for this modality. The current data helps answer a crucial third question: identifying which patients and tumor types are suited for this approach.

The findings presented at the Japanese Cancer Association meeting highlight the potential of SL Science's γδ T cell therapy platform in addressing the limitations of standard chemotherapy for glioblastoma. The Company continues to advance its research with the goal of developing innovative cellular and gene therapies to revolutionize cancer treatment.